This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Analyst Reports for Eli Lilly, Mitsubishi UFJ & Thermo Fisher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Mitsubishi UFJ Financial Group, Inc. (MUFG) and Thermo Fisher Scientific Inc. (TMO).
Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study
by Zacks Equity Research
Eli Lilly's (LLY) Taltz displays superiority over standard of care medicine Humira in a head-to-head study on patients with active psoriatic arthritis.
Teva Reports Positive Top-Line Data for Migraine Candidate
by Zacks Equity Research
Teva (TEVA) announces positive top-line data from the phase IIIb study on fremanezumab for the preventive treatment of migraine in adult patients.
Merck to Acquire Europe's Antelliq Group for $2.4 Billion
by Zacks Equity Research
Merck (MRK) secures an acquisition deal to purchase French animal health company Antelliq Group for a consideration of around $2.4 billion.
Incyte (INCY) Collaborates with Innovent for 3 Candidates
by Zacks Equity Research
Incyte (INCY) collaborates with Innovent for the development of three clinical-stage product candidates: pemigatinib, itacitinib and parsaclisib.
Lilly (LLY) to Acquire Pain Candidate From Private Biotech
by Zacks Equity Research
Lilly (LLY) inks a deal with privately held Hydra Biosciences to add the latter's pre-clinical pain candidate to its portfolio.
J&J Dips 10% as Reuters Says Company Knew of Asbestos in Talc
by Zacks Equity Research
A Reuters article says that J&J (JNJ) knew for decades that its baby powders contained asbestos. J&J stock dips 10%.
Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus
by Zacks Equity Research
Mylan (MYL) gets a favorable ruling from the U.S. PTAB against Sanofi for Lantus.
Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019
by Zacks Equity Research
The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.
Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.
Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?
by Sweta Killa
Smart Beta ETF report for FLQL
Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug
by Zacks Equity Research
Eli Lilly (LLY) signs a deal with AC Immune to jointly develop Morphomer tau aggregation inhibitors, which have the potential to treat Alzheimer's disease (AD) and other neurodegenerative diseases.
Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800
by Zacks Equity Research
Bristol-Myers (BMY) enters into a collaboration agreement with Vedanta Biosciences to study Opdivo clubbed with the latter's VE800 for treating patients with advanced or metastatic cancers.
The Zacks Analyst Blog Highlights: Eli Lilly, Anthem, BlackRock, CME Group and Southern Company
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Anthem, BlackRock, CME Group and Southern Company
Mallinckrodt (MNK) to Separate Generics & Branded Businesses
by Zacks Equity Research
Mallinckrodt (MNK) announces plans to split its generic and branded businesses into two different companies.
Top Stock Reports for Eli Lilly, Anthem & BlackRock
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (LLY), Anthem (ANTM) and BlackRock (BLK).
Why Is Lilly (LLY) Up 6.2% Since Last Earnings Report?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Eli Lilly (LLY) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
The Zacks Analyst Blog Highlights: Verizon, Eli Lilly, Accenture, VMware and Schwab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verizon, Eli Lilly, Accenture, VMware and Schwab
Incyte (INCY) Announces Positive Data on Jakafi for GVHD
by Zacks Equity Research
Incyte (INCY) announces positive data on lead drug Jakafi at the ASH meet for the indication of acute GVHD.
Top Stock Reports for Verizon, Eli Lilly & Accenture
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Verizon (VZ), Eli Lilly (LLY) and Accenture (ACN).
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $118.64 in the latest trading session, marking a +1.4% move from the prior day.
Lilly (LLY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Merck (MRK) Receives Approval for 2 HIV Medicines in EU
by Zacks Equity Research
Merck's (MRK) two new HIV drugs, Pifeltro and Delstrigo, containing doravirine, get approval in EU.